DBVT DBV Technologies S.A.

-

DBV Technologies S.A. Missed Consensus Estimates

Thursday, July 16, 2026 · 12:00 AM ET

DBV Technologies S.A. (DBVT) reported a loss of $0.60 per share on revenue of $0.70 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.12 per share on revenue of $1.00 million. The company missed consensus estimates by 400.00% while revenue fell 52.22% compared to the same quarter a year ago.

DBV Technologies SA is an epicutaneous immunotherapy company. The Company is engaged in research and development of patient-friendly therapy for food and pediatric allergy patients.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.60)
Earnings Whisper®
Consensus Estimate
($0.12)
Earnings Surprise
Earnings Growth61.3 %
Reported Revenue
$0.70M
Revenue Estimate
$1.00M
Revenue Surprise
Revenue Growth-52.2 %